Oramed Pharmaceuticals Inc. (TLV:ORMP)

Oramed Pharmaceuticals Statistics

Total Valuation

TLV:ORMP has a market cap or net worth of ILS 329.02 million. The enterprise value is 8.14 million.

Market Cap	329.02M
Enterprise Value	8.14M

Important Dates

The next estimated earnings date is Friday, November 7, 2025.

Earnings Date	Nov 7, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	41.00M
Shares Outstanding	n/a
Shares Change (YoY)	-0.21%
Shares Change (QoQ)	+3.35%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	32.64M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	48.83
PB Ratio	0.64
P/TBV Ratio	0.63
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-0.10
EV / Sales	1.24
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.15

Financial Position

The company has a current ratio of 26.81, with a Debt / Equity ratio of 0.01.

Current Ratio	26.81
Quick Ratio	26.69
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	-0.06
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -14.69% and return on invested capital (ROIC) is -5.16%.

Return on Equity (ROE)	-14.69%
Return on Assets (ROA)	-4.94%
Return on Invested Capital (ROIC)	-5.16%
Return on Capital Employed (ROCE)	-8.65%
Revenue Per Employee	1.68M
Profits Per Employee	-20.35M
Employee Count	4
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

In the past 12 months, TLV:ORMP has paid 6.76 million in taxes.

Income Tax	6.76M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -8.18% in the last 52 weeks. The beta is 1.62, so TLV:ORMP's price volatility has been higher than the market average.

Beta (5Y)	1.62
52-Week Price Change	-8.18%
50-Day Moving Average	739.56
200-Day Moving Average	791.09
Relative Strength Index (RSI)	73.20
Average Volume (20 Days)	10,647

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.52

Income Statement

In the last 12 months, TLV:ORMP had revenue of ILS 6.74 million and -81.41 million in losses. Loss per share was -2.03.

Revenue	6.74M
Gross Profit	43,801
Operating Income	-46.07M
Pretax Income	-74.85M
Net Income	-81.41M
EBITDA	-45.59M
EBIT	-46.07M
Loss Per Share	-2.03

Balance Sheet

The company has 329.99 million in cash and 3.07 million in debt, giving a net cash position of 326.92 million.

Cash & Cash Equivalents	329.99M
Total Debt	3.07M
Net Cash	326.92M
Net Cash Per Share	n/a
Equity (Book Value)	517.47M
Book Value Per Share	12.75
Working Capital	321.21M

Cash Flow

In the last 12 months, operating cash flow was -54.13 million and capital expenditures -77,494, giving a free cash flow of -54.21 million.

Operating Cash Flow	-54.13M
Capital Expenditures	-77,494
Free Cash Flow	-54.21M
FCF Per Share	n/a

Margins

Gross Margin	0.65%
Operating Margin	-683.65%
Pretax Margin	-1,110.80%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

TLV:ORMP does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.21%
Shareholder Yield	n/a
Earnings Yield	-24.74%
FCF Yield	-16.48%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

TLV:ORMP has an Altman Z-Score of 5.98 and a Piotroski F-Score of 1.

Altman Z-Score	5.98
Piotroski F-Score	1